Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
The firm said that it delivered more than 29,990 test results in the third quarter of 2016 compared to 27,820 results delivered in Q3 2015.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
The results showed overall high concordance between test results and whether patients received chemotherapy, with some relevant exceptions.
The company is moving forward in working with early adopters in a limited setting of lung cancer testing, but still plans to expand its test to other cancers soon.
The model could shift which patients receive gene expression profiling assays but might not change the number of tests ordered.
The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.
Under the agreement, Genomic Health will make an undisclosed equity investment in Epic Sciences, and will have exclusive rights to market its test in the US.
The company has limited its use initially to a group of early-access physicians and centers in order to build familiarity and establish the utility of the assay.
Some of the proposed payment rates for 2017 are low, but diagnostics firms will likely try to negotiate higher pricing during the 30-day comment period.
In Science this week: genetic analysis of pollutant-tolerant fish, and more.
Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.
New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.
NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.